See the DrugPatentWatch profile for lysteda
What is Lysteda (tranexamic acid) NDA 022430, and what’s in its approval package?
NDA 022430 is the U.S. marketing application for Lysteda (tranexamic acid), an antifibrinolytic drug. The “approval package” for an FDA NDA generally includes the application summary materials, review documents, labeling, and the FDA’s approval action/letter for the application.
I don’t have the specific contents of the NDA 022430 approval package in the information provided here, so I can’t list which exact review memos or documents are included without a source for the NDA file contents.
Where can you find the NDA 022430 approval letter and review documents?
For Lysteda NDA 022430, the most common places to look for the approval package materials are FDA’s public repositories (including drug review and approval documentation when available), such as:
- FDA Drugs@FDA (for the approval history and labeling references tied to the NDA number)
- FDA’s drug approval package links (when FDA has posted the full documents for that NDA)
- Public FDA review document libraries (where accessible)
If you share the link you’re using (or paste the document list you see), I can summarize what each document is and what it implies about the evidence FDA relied on.
What evidence and clinical data typically supported Lysteda’s NDA approval?
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. For NDA approvals of drugs like Lysteda, the FDA typically relies on:
- Controlled clinical trials showing reduction in the target bleeding outcome versus placebo
- Safety data across the studied population
- Benefit-risk assessment, including thromboembolic risk considerations consistent with the drug’s mechanism
To describe what specific trials were included in NDA 022430, I’d need the approval package contents or the FDA review summaries for that specific NDA.
What did FDA approve under NDA 022430 (indication and labeling scope)?
NDA labeling typically includes:
- Approved indication (what condition it treats)
- Dosage and administration instructions
- Key safety warnings and contraindications
- Clinical study results summary language
If you provide the labeling section text or the FDA label version date, I can identify exactly what was approved and how it may differ from later label updates.
Who holds the NDA for Lysteda, and has anything changed since approval?
Drug labeling, indications, and safety warnings can change after initial approval due to:
- Post-marketing safety updates
- Labeling revisions from additional data
- Regulatory actions or risk-management updates
To answer for NDA 022430 specifically, I need the current FDA Drugs@FDA record or the specific approval package documents you’re referencing.
If you’re trying to request the full FDA NDA file, how does that work?
If you’re after documents that aren’t posted publicly, there are two common routes:
- FDA public posting of review/approval documents (when available)
- Freedom of Information Act (FOIA) requests for non-public materials
If you tell me whether your goal is (a) the approval letter only, (b) full reviews, or (c) the entire NDA file, I can outline the fastest likely path.
---
Sources
No sources were provided in your message, so I did not cite any.